{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:01:37Z","timestamp":1769547697769,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.mehy.2021.110545","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T19:45:57Z","timestamp":1613677557000},"page":"110545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["COVID-19-related arrhythmias and the possible effects of ranolazine"],"prefix":"10.1016","volume":"149","author":[{"given":"Ugochukwu","family":"Chukwunyere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Ozer","family":"Sehirli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurettin","family":"Abacioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.mehy.2021.110545_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2021.110545_b0010","unstructured":"COVID-19 Map In. Johns Hopkins Coronavirus Resource Center [Online]. Available: https:\/\/coronavirus.jhu.edu\/map.html. [Accessed 2 January 2020]."},{"issue":"7","key":"10.1016\/j.mehy.2021.110545_b0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.mehy.2021.110545_b0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.mehy.2021.110545_b0025","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.mehy.2021.110545_b0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/erc.11.91","article-title":"Ranolazine: an antianginal drug with antiarrhythmic properties","volume":"9","author":"Tamargo","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"8","key":"10.1016\/j.mehy.2021.110545_b0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hrthm.2011.03.045","article-title":"Electrophysiologic basis for the antiarrhythmic actions of ranolazine","volume":"8","author":"Antzelevitch","year":"2011","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.mehy.2021.110545_b0040","doi-asserted-by":"crossref","first-page":"e0150619","DOI":"10.1371\/journal.pone.0150619","article-title":"Effects of ranolazine on astrocytes and neurons in primary culture","volume":"11","author":"Aldasoro","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.mehy.2021.110545_b0045","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12805","article-title":"Electrocardiograhic characteristics in patients with coronavirus infection: a single-center observational study","volume":"25","author":"Li","year":"2020","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"11","key":"10.1016\/j.mehy.2021.110545_b0050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0055","doi-asserted-by":"crossref","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.mehy.2021.110545_b0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.mehy.2021.110545_b0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS corona- virus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.mehy.2021.110545_b0070","doi-asserted-by":"crossref","unstructured":"Mathewson AC, Bishop A, Yao Y, Kemp F, et al (2008) Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. J. Gen. Virol, 89(11):2741. doi: 10.1099\/vir.0.2008\/003962-0.","DOI":"10.1099\/vir.0.2008\/003962-0"},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0075","first-page":"518","article-title":"COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies","volume":"5","author":"Atri","year":"2020","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases?","volume":"20","author":"Schett","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.mehy.2021.110545_b0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10223","key":"10.1016\/j.mehy.2021.110545_b0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mehy.2021.110545_b0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.yjmcc.2007.09.004","article-title":"SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent ICaL, [Ca2+]i transient, and APD increase in cardiomyocytes","volume":"43","author":"Hagiwara","year":"2007","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110545_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13344","article-title":"Macrophage-dependent IL-1\u03b2 production induces cardiac arrhythmias in diabetic mice","volume":"7","author":"Monnerat","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.mehy.2021.110545_b0110","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3389\/fphys.2018.01866","article-title":"Cardiolipotoxicity, inflammation, and arrhythmias: role for interleukin-6 molecular mechanisms","volume":"9","author":"Al\u00ed","year":"2019","journal-title":"Front Physiol"},{"issue":"14","key":"10.1016\/j.mehy.2021.110545_b0115","doi-asserted-by":"crossref","first-page":"13289","DOI":"10.1074\/jbc.C400025200","article-title":"Impairment of HERG K (+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator","volume":"279","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.mehy.2021.110545_b0120","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1113\/JP273873","article-title":"KATP channel inhibition blunts electromechanical decline during hypoxia in left ventricular working rabbit hearts","volume":"595","author":"Garrott","year":"2017","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110545_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12966","article-title":"Fhf2 gene deletion causes temperature-sensitive cardiac conduction failure","volume":"7","author":"Park","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.mehy.2021.110545_b0130","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.hrthm.2015.05.027","article-title":"Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential","volume":"12","author":"Capel","year":"2015","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.mehy.2021.110545_b0135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12012-017-9401-7","article-title":"Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin","volume":"17","author":"Zhang","year":"2017","journal-title":"Cardiovasc Toxicol"},{"issue":"9","key":"10.1016\/j.mehy.2021.110545_b0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacep.2020.05.015","article-title":"Atrial arrhythmias in COVID-19 Patients","volume":"6","author":"Colon","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.mehy.2021.110545_b0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/1568010042634578","article-title":"PPARs as drug targets to modulate inflammatory responses?","volume":"3","author":"Genolet","year":"2004","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"20","key":"10.1016\/j.mehy.2021.110545_b0150","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2021.110545_b0155","first-page":"353","article-title":"Update on ranolazine in the management of angina","volume":"10","author":"Codolosa","year":"2014","journal-title":"Vasc Health Risk Manage"},{"issue":"8","key":"10.1016\/j.mehy.2021.110545_b0160","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electro- physiological effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2021.110545_b0165","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.704890","article-title":"Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine","volume":"116","author":"Burashnikov","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.mehy.2021.110545_b0170","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.hrthm.2008.03.018","article-title":"Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations","volume":"5","author":"Sicouri","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.mehy.2021.110545_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152571301150730113903","article-title":"Ranolazine and its antiarrhythmic actions","volume":"13","author":"Polytarchou","year":"2015","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.mehy.2021.110545_b0180","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1540-8159.2011.03298.x","article-title":"The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series","volume":"35","author":"Murdock","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.mehy.2021.110545_b0185","unstructured":"D.K. Murdock J.W. Kaliebe Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report Indian Pacing Electrophysiol J 11 3 2011 84 88 PMCID: PMC3083144."},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0190","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY Trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0195","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","article-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting","volume":"108","author":"Miles","year":"2011","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.mehy.2021.110545_b0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/anec.12137","article-title":"Ranolazine for the suppression of ventricular arrhythmia: a case series","volume":"19","author":"Yeung","year":"2014","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"15","key":"10.1016\/j.mehy.2021.110545_b0205","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2021.110545_b0210","doi-asserted-by":"crossref","unstructured":"Karwatowska-Prokopczuk, E, Wang W, Cheng ML, Zeng D, Schwartz PJ, Belardinelli L (2013) The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: Effect of ranolazine. Europace, 15:4. doi: 10.1093\/europace\/eus400.","DOI":"10.1093\/europace\/eus400"},{"issue":"5","key":"10.1016\/j.mehy.2021.110545_b0215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin Pharmacokinet"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:23:47Z","timestamp":1759692227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":43,"alternative-id":["S0306987721000633"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110545","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19-related arrhythmias and the possible effects of ranolazine","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110545"}}